What is Cerezyme, and who sells it in the UK?
Cerezyme is the brand name for imiglucerase, an enzyme replacement therapy used to treat Gaucher disease. The drug is supplied in the UK by Sanofi and marketed under the Cerezyme name. [1]
How big is the Cerezyme market in the UK?
A precise “market size” number for the UK is not provided in the available information. Market demand for Cerezyme in the UK depends mainly on the number of diagnosed Gaucher disease patients who are eligible for enzyme replacement therapy and on uptake versus competing therapies (see below). [1]
What competes with Cerezyme in the UK market?
Cerezyme competes with other enzyme replacement therapies for Gaucher disease, including:
- Vpriv (velaglucerase alfa)
- Elelyso (taliglucerase alfa)
These alternatives can affect pricing pressure and prescribing patterns. [1]
Why would UK demand for Cerezyme change over time?
UK demand can shift due to factors such as:
- changes in diagnosed patient numbers,
- treatment switching from older ERT products to other available ERTs,
- payer and formulary decisions,
- drug supply and any policy changes affecting access to expensive specialty medicines.
No UK-specific timeline is given in the provided information. [1]
Where can you find UK availability and prescribing info?
For UK product access context (including manufacturer/supplier information), use the UK product listing and medicine information sources that identify the brand and its manufacturer. [1]
Sources:
[1] https://www.medicalnewstoday.com/articles/cerezyme